Final results from a phase II study presented at ASCO show that 25% of women with advanced HER2-positive breast cancer experienced significant shrinkage of their tumours, when treated with a first in class combination antibody called trastuzumab-DM1 (T-DM1). T-DM1 potentially represents another option for patients with metastatic disease, for which there is no cure.
More...
Linear Mode
